Figure 1. Proximity to Parental Symptom Onset and Amyloid-β (Aβ) Burden in the Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) Cohort.

P values were obtained with linear regression models controlled for age, sex, and educational level. Analyses that include the sporadic parental estimated years to symptom onset (EYO) score (calculated as the age of the participant at assessment minus the age of the parent at symptom onset) × APOE status interaction were also controlled for the main effect of APOE status. Unadjusted (raw) data are plotted. APOE4 indicates apolipoprotein E ɛ4; CSF, cerebrospinal fluid.